modelRosuvastatinAndAcetylsalicylicAc
Extends from Pharmacolibrary.Drugs.ATC.C.C10BX05.
Information
| name: | RosuvastatinAndAcetylsalicylicAcid |
| ATC code: | C10BX05 | route: | oral |
| n-compartments | 1 |
Rosuvastatin and acetylsalicylic acid is a fixed-dose combination medicinal product containing rosuvastatin, a statin used to lower cholesterol and prevent cardiovascular disease, and acetylsalicylic acid (aspirin), an antiplatelet agent used for secondary prevention of cardiovascular events. This combination is approved for use in adults at risk of or with established cardiovascular disease.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult subjects based on individual component published data; no fixed-dose combination specific PK study identified.
References
Danielak, D, et al., & Główka, F (2018). Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 78(11) 1105–1112. DOI:10.1007/s40265-018-0947-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/30003466
Pincus, KJ, & Hynicka, LM (2013). Prophylaxis of thromboembolic events in patients with nephrotic syndrome. The Annals of pharmacotherapy 47(5) 725–734. DOI:10.1345/aph.1R530 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23613095
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 initial generated model